Jaguar Animal Health Inc (NASDAQ:JAGX) an animal health company which specializes in the development, marketing and commercialization of gastrointestinal products for foals, production animals and high value horses has entered into a merger agreement with Napo Pharmaceuticals, Inc. the agreement was unanimously approved by both companies’ Board of Directors. Upon full execution of the agreement, Napo will become Jaguar’s fully owned subsidiary specializing in human health.
Among the terms of the agreement is a 3-to-1 Napo-to-Jaguar value ratio that will be the basis for calculating the ownership of the merged company. At the end of January, Napo had around 19% of all outstanding shares in Jaguar.
Jaguar’s president and CEO who also sums up as interim CEO of Napo Lisa Conte in a statement said it is an opportune moment to merge the two entities adding that the merger agreement will be in the best interest of both companies and their stockholders. She adds that upon completion of the merger, the two companies will experience value-adding benefits especially a stream of revenue from Mytesi™, a prescription product a prescription product initially called Fulyzaq. She expressed optimism that the two companies through the joint management team will increase efficiencies as well as increase value.
The combination of the two entities will offer Jaguar with an important opportunity to realize revenue stream from the sale of Mytesi™. Mytesi™ has been approved by the FDA for treatment of noninfectious diarrhea in HIV/AIDS infected adults on antiretroviral therapy. The drug was launched by Napo in October 2016. According to the two companies, the potential market for the drug in the U.S. is around $100 million.
Napo is using a direct sales initiative in an effort to promote the drug to HIV paints in the second quarter of 2017 with telesales and live representatives. Both companies have set the sales target from the drug at around $7.0 million in 2017. Mytesi™’s active pharmaceutical ingredient (API) is crofelemer. Napo is seeking global partnerships to develop, market and commercialize the drug. The company is still developing the drug for other potential antidiarrheal indications with investigational trials completed for cholera, irritable bowel syndrome, traveler’s diarrhea as well as in pediatric patients
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.financialstrend.com